These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 4704107

  • 1. Study of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in patients with disseminated melanoma.
    Gerner RE, Moore GE.
    Cancer Chemother Rep; 1973 Feb; 57(1):83-4. PubMed ID: 4704107
    [No Abstract] [Full Text] [Related]

  • 2. Intra-arterial infusion therapy with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC 45388) for malignant melanoma.
    Einhorn LH, McBride CM, Luce JK, Caoili E, Gottlieb JA.
    Cancer; 1973 Oct; 32(4):749-55. PubMed ID: 4751911
    [No Abstract] [Full Text] [Related]

  • 3. 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of lymphoma.
    Frei E, Luce JK, Talley RW, Vaitkevicius VK, Wilson HE.
    Cancer Chemother Rep; 1972 Oct; 56(5):667-70. PubMed ID: 4569060
    [No Abstract] [Full Text] [Related]

  • 4. 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of advanced acute lymphocytic leukemia in children.
    Finklestein JZ, Albo V, Ertel I, Karon M, Hammond D.
    Cancer Chemother Rep; 1972 Aug; 56(4):523-6. PubMed ID: 4507686
    [No Abstract] [Full Text] [Related]

  • 5. Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin.
    Gutterman JU, Mavligit G, Gottlieb JA, Burgess MA, McBride CE, Einhorn L, Freireich EJ, Hersh EM.
    N Engl J Med; 1974 Sep 19; 291(12):592-7. PubMed ID: 4851001
    [No Abstract] [Full Text] [Related]

  • 6. Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide.
    Gottlieb JA, Baker LH, Quagliana JM, Luce JK, Whitecar JP, Sinkovics JG, Rivkin SE, Brownlee R, Frei E.
    Cancer; 1972 Dec 19; 30(6):1632-8. PubMed ID: 4663966
    [No Abstract] [Full Text] [Related]

  • 7. Clinical experience with 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) in the treatment of metastatic malignant melanoma.
    Falkson G, Van der Merwe AM, Falkson HC.
    Cancer Chemother Rep; 1972 Oct 19; 56(5):671-7. PubMed ID: 4569061
    [No Abstract] [Full Text] [Related]

  • 8. Chemotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and dactinomycin.
    Gerner RE, Moore GE, Didolkar MS.
    Cancer; 1973 Oct 19; 32(4):756-60. PubMed ID: 4751912
    [No Abstract] [Full Text] [Related]

  • 9. Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388).
    Luce JK, Thurman WG, Isaacs BL, Talley RW.
    Cancer Chemother Rep; 1970 Apr 19; 54(2):119-24. PubMed ID: 4334086
    [No Abstract] [Full Text] [Related]

  • 10. Central nervous system complications after combination treatment with adriamycin (NSC-123127) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).
    Gams RA, Carpenter JT.
    Cancer Chemother Rep; 1974 Apr 19; 58(5 Pt 1):753-4. PubMed ID: 4214608
    [No Abstract] [Full Text] [Related]

  • 11. [Polychemotherapy with 5-(3,3 dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC; NSC-45388), 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC-409962) and vincristine (NSC-67574) in the metastatic phase of melanoma].
    Beretta G, Bajetta E, Bonadonna G, Tancini G, Orefice S, Veronesi U.
    Tumori; 1973 Apr 19; 59(3):239-48. PubMed ID: 4729646
    [No Abstract] [Full Text] [Related]

  • 12. Hexamethylmelamine (NSC-13875) alone and in combination with 5-(3, 3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388) in the treatment of advanced cancer.
    Stolinsky DC, Bogdon DL, Solomon J, Bateman JR.
    Cancer; 1972 Sep 19; 30(3):654-9. PubMed ID: 5075351
    [No Abstract] [Full Text] [Related]

  • 13. Effective treatment of Kaposi's sarcoma with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).
    Vogel CL, Primack A, Owor R, Kyalwazi SK.
    Cancer Chemother Rep; 1973 Feb 19; 57(1):65-71. PubMed ID: 4704105
    [No Abstract] [Full Text] [Related]

  • 14. Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma.
    Nathanson L, Wolter J, Horton J, Colsky J, Shnider BI, Schilling A.
    Clin Pharmacol Ther; 1971 Feb 19; 12(6):955-62. PubMed ID: 5134998
    [No Abstract] [Full Text] [Related]

  • 15. 5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma.
    Carter SK, Friedman MA.
    Eur J Cancer (1965); 1972 Feb 19; 8(1):85-92. PubMed ID: 4552317
    [No Abstract] [Full Text] [Related]

  • 16. Therapy of malignant melanoma with an imidazole carboxamide and bis-chloroethyl nitrosourea.
    Costanza ME, Nathanson L, Lenhard R, Wolter J, Colsky J, Oberfield RA, Schilling A.
    Cancer; 1972 Dec 19; 30(6):1457-61. PubMed ID: 4641757
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase II study of 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) in advanced gastrointestinal cancer.
    Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG.
    Cancer Chemother Rep; 1972 Apr 19; 56(2):267-9. PubMed ID: 5043230
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.